ADAM9 and Familial prostate cancer: Josson et al. first demonstrates the inhibition of ADAM9 enhances the sensitivity to numerous common chemotherapy drugs (including doxorubicin, cisplatin, and gemcitabine) in prostate cancer cells [110].